Abstract:
본 발명은 류코트리엔 생성 저해활성을 가지는 신이 (Magnoliae flos) 추출물 및 신이로부터 분리한 리그난 화합물에 관한 것으로, 신이를 유기용매로 추출하여 얻어지는 본 발명의 신이 추출물 및 이로부터 분리되는 하기 화학식 1 내지 화학식 7의 리그난 화합물은 류코트리엔 생성 저해제로서 류코트리엔과 관련된 질환의 예방, 치료 및 치료보조제로 유용하게 사용될 수 있다. [화학식 1]
Abstract:
PURPOSE: A pharmaceutical composition containing hematein which is obtainable by extraction of Heartwood of Caesalpinia sappan or commercially as an active ingredient is provided. Because the hematein exhibits LDL-antioxidant activity, remarkably reduces cholesterol in blood and strongly inhibits liver microsome ACAT activity, the composition can be effectively used in prevention and therapeutic treatment of atherosclerosis and hyperlipidemia. CONSTITUTION: The composition for preventing and treating atherosclerosis and hyperlipidemia in mammals contains an effective amount of hematein and a pharmaceutically acceptable carrier as an active component. The hematein inhibits the activity of acyl-CoA : cholesterol acyltransferase or acts as LDL-antioxidant to give an effect on preventing and treating hyperlipidemia.
Abstract:
PURPOSE: Schizandrin having antagonistic activity on a platelet activating factor receptor isolated from Schisandrae fructus, a pharmaceutical composition containing the compound, pharmaceutically acceptable carrier and excipient and their use are provided. Therefore the composition can be used for treatment and prevention of inflammatory disease related to a platelet activating factor. CONSTITUTION: An antagonist on a platelet activating factor receptor contains schizandrin A, B or C of formula 3 isolated from Schisandrae fructus as an effective component. In formula, a compound in which R1, R2, R3 and R4 are respectively CH3O is schizandrin A; a compound in which R1 and R2 are respectively CH3O, and R3 and R4 are connected to OCH2O is schizandrin B; and a compound in which R3 and R4 are connected to OCH2O is schizandrin C. A pharmaceutical composition for treatment and prevention of inflammatory disease related to a platelet activating factor contains the schizandrin, pharmaceutically acceptable carrier and excipient.
Abstract:
PURPOSE: A pharmaceutical composition containing essential oil as an active principle for inhibiting production of leukotriene is useful for prevention and treatment of the diseases related with the activity of leukotriene such as asthma, cystic fibrosis, septic shock, cardiac anaphylaxis, cerebral vasospasm, psoriasis, endotoxemia, myocardial ischemia, etc.. CONSTITUTION: A main component of the essential oil is more than one compound selected from (-)-menthol, (+)-limonene, alpha-terpinene, gamma-terpinene, terpineol, beta-myrcene, (+or-)-linalool, geraniol, citral, beta-cyclocitral, eugenol, safrol, (+)-alpha-pinene, (-)-alpha-pinene and (+)-cis-verbenol.
Abstract:
본 발명은 흰점박이 꽃무지로부터 분리한 신규 항생물질 프로테신, 그의 제조방법 및 이를 유효성분으로 하는 항생제에 관한 것이다. 프로테신은 자연 상태의 흰점박이 꽃무지로부터, 또는 물리적 자극, 미생물 또는 기타 이물질을 주입한 흰점박이 꽃무지로부터 추출할 수 있으며 지금까지 알려지지 않은 신규의 항생물질 이다.
Abstract:
PURPOSE: A haematin substance has characteristically an LDL(low density lipoprotein)-antioxidation, reduces the concentration of cholesterol in blood, and inhibits the activity of liver microsome ACAT(acyl-CoA: cholesterol acyl-transferase). Thereby, the pharmaceutical composition containing the haematin has an excellent effect for treating or protecting specific diseases such as hyperlipidemia or arteriosclerosis. CONSTITUTION: The haematin used is conventionally derivable from Heartwood of Caesalpinia sappan, or is available industrially. The pharmaceutical composition is used to treat or protect hyperlipidemia or arteriosclerosis by using usual haematin in drug, beverage or food.
Abstract:
본 발명은 화학식 1 및 화학식 2 로 표시되는 새로운 리그난 화합물에 관한 것이다.
또한, 본 발명은 신이 (Magnoliae flos)로부터 화학식 1 및 화학식 2 의 화합물을 제조하는 방법에 관한 것이다. 또한, 본 발명은 새로운 화학식 1 및 화학식 2 의 화합물을 유효 성분으로 하는 혈소판 활성화 인자 (platelet-activating factor, PAF) 수용체에 작용하는 길항제에 관한 것으로서, 이는 상기 혈소판 활성화 인자와 관련된 염증성 질환의 예방 및 치료에 유용하게 사용될 수 있다. 또한, 본 발명은 신이 추출물 및 이를 유효 성분으로 하는 혈소판 활성화 인자 수용체에 작용하는 길항제에 관한 것이다.
Abstract:
PURPOSE: Provided is a novel use of essential oil obtained by vapor distillation of plants and showing the inhibitory action against the production of leukotriene as a mediator of inflammation. CONSTITUTION: An inhibitor of leukotriene production comprises at least a compound selected from the group consisting of (-)-menthol, (+)-limonene, alpha-terpinene, gamma-terpinene, terpineol, beta-myrcene, (±)-linaloo, geraniol, citral, beta-cyclocitral, eugenol, safrole, (+)-alpha-pinene, (-)-alpha-pinene, and (+)-cis-verbenol, as an effective components. Preferably, the inhibitor comprises eugenol or safrole as an active ingredient. The inhibitor can be used for a variety of inflammatory diseases including asthma, whooping cough, psoriasis, arthritis, inflammatory intestine diseases, cystic fibrosis, chronic bronchitis, rheumatoid arthritis, septic shock, myocardial ischemia, cardiac anaphylaxis, cerebral vasospasm, ischemia and allergic rhinitis.